Ask about this productRelated genes to: CD70 antibody
- Gene:
- CD70 NIH gene
- Name:
- CD70 molecule
- Previous symbol:
- CD27LG, TNFSF7
- Synonyms:
- CD27L
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-11-08
- Date modifiied:
- 2016-10-05
Related products to: CD70 antibody
Related articles to: CD70 antibody
- Cusatuzumab is a monoclonal antibody that binds with high affinity to CD70, a cell surface protein overexpressed on CD34+ acute myeloid leukemia (AML) progenitors and leukemia stem cells. This phase Ib study assessed the safety, tolerability and efficacy of adding cusatuzumab to standard-of-care azacitidine and venetoclax (CVA) or a cusatuzumab and venetoclax (CV) doublet regimen in patients newly diagnosed with AML who were ineligible for intensive chemotherapy. Cusatuzumab 20 mg/kg was administered intravenously on days 3 and 17 of 28-day cycles combined with standard dosing of venetoclax ± azacitidine. Overall, 44 patients were treated with CVA. Common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (77.3%), thrombocytopenia (77.3%) and anemia (45.5%); non-hematologic TEAEs included nausea (45.5%), diarrhea (43.2%), constipation (40.9%), fatigue (36.4%) and vomiting (31.8%). Grade ≥3 infectious complications included febrile neutropenia (38.6%), sepsis (36.4%) and pneumonia (9.1%). The overall composite response rate (complete remission [CR] + CR with partial hematologic recovery [CRh] + CR with incomplete hematologic recovery [CRi]) was 77.3% (CR, 47.7%; CRh, 20.5%; CRi, 9.1%). Among CR/CRi responders, 53% achieved negative measurable residual disease by multiparameter flow cytometry. Median overall survival was 12.0 months (95% confidence interval: 8.7-NE) months. Sixteen patients were treated with CV and had similar safety but less favorable responses and survival than those treated with CVA. These results support further development of CVA for the treatment of AML (clinicaltrials.gov identifier: NCT04150887). - Source: PubMed
Publication date: 2026/09/03
Roboz Gail JPabst ThomasAribi AhmedBrandwein Joseph MDöhner HartmutFiedler WalterRiether CarstenGandini DomenicaGeddes MichelleHou Jing-ZhouYee KarenHultberg AnnaHuselton EricJacobs JulieZabrocki PiotrLech-Marańda EwaLouwers MariekeNottage KerriPlatzbecker UweRampal RaajitSalman MashaShah PriyaWilson KaylaStuart MonicSubklewe MarionSumbul AnneWang Eunice SWierzbowska AgnieszkaYao BinPatel RaviGeorge AdamIslam NazmulSmith ClayBoyiadzis MichaelBorthakur Gautam - - Source: PubMed
Publication date: 2026/09/02
Wei WeijunBurger IreneZhang JinHerrmann KenShuch Brian M - Artificial intelligence (AI) is accelerating antimicrobial peptide (AMP) discovery, but prediction-centered workflows often overlook dataset redundancy, peptide synthesizability, and experimental anti-infective translation. Here, we developed a redundancy-aware AI-guided peptide discovery workflow integrating redundancy-controlled dataset construction, model interpretation, candidate screening, synthesis-linked experimental validation, and evaluation in an infected-wound model. A redundancy-retention (RR) dataset of 1861 peptides with E. coli MIC annotations was compared with CD-HIT-filtered CD60-CD90 datasets containing 439-1061 sequences. Redundancy control reshaped activity-density distributions, SHAP-derived feature dependence, and virtual-screening stringency. Screening 2.1 million random 13-mer peptides yielded 1763, 189, 157, 141, and 20 candidates from CD60, CD70, CD80, CD90, and RR workflows, respectively. Experimental synthesis and MIC testing showed that the RR-derived group had a higher mean crude yield and a higher hit rate against E. coli than the CD90-derived group (60% vs 20%; MIC ≤16 μM). The lead peptide A36 showed broad activity against the tested Gram-negative bacteria, inhibited drug-resistant clinical A. baumannii isolates, displayed low hemolysis and cytotoxicity, retained substantial integrity in serum and antibacterial activity after protease exposure, disrupted bacterial membranes, and reduced bacterial burden while promoting wound closure in an A. baumannii-infected wound model. These findings identify redundancy control as a practical factor influencing candidate selection, synthetic accessibility, and experimental hit recovery in AI-guided AMP discovery. - Source: PubMed
Publication date: 2026/08/31
Deng YaboGu MengyunRen XinluMeng JiannaGuo HaiXie YihaoYu YunxiangZhang ZhouZhou YiWu YunkeChen DannaShen ZhiqiangYan JiexiHan JianYan WenjinHuang Jinqi - Chimeric antigen receptor (CAR) therapies have shown great success in hematological malignancies but remain largely ineffective against solid tumors such as pancreatic ductal adenocarcinoma (PDAC). A key obstacle among various aspects, is the dense stromal barrier formed by cancer-associated fibroblasts (CAFs), providing a rationale for simultaneously targeting stroma and tumor cells. Using immunohistochemistry of primary PDAC tumors and liver metastases, we confirmed high mesothelin (MSLN) expression on tumor cells, and CD70 expression on tumor cells and predominantly CAFs. Based on these results and the favorable safety profile of CAR natural killer (NK) cells over CAR T cells, we generated MSLN- and CD70-targeting IL-15-armored CAR NK cells. Both constructs mediated cytotoxicity against different pancreatic cancer and CAF cell lines with varying antigen expression , demonstrating that both, the CAR-molecule and IL-15 were required to increase functionality against more treatment-resistant cell lines. Interestingly, pooled MSLN- and CD70-CAR NK cells did not significantly improve cytolysis compared to monotherapies in an advanced 3D model or . Together these findings highlight the limitations of dual-targeting approaches and underscore the need for advanced engineering strategies to improve CAR NK cells beyond antigen targeting and cytokine support in the PDAC microenvironment. - Source: PubMed
Publication date: 2026/08/05
Gehrcken LauraOtt JasperVan den Eynde AstridLau Ho WaLiu DanaHermans ChristopheVerhezen TiasPeeters StefanieFaghel CaroleJoye PhilippeRoex GilsCampillo-Davo DianaLion EvaElvas FilipeKoljenovic SenadaDe Waele JorritHartman VeraRoeyen GeertPrenen HansLardon FilipDeben ChristopheSmits EvelienVan Audenaerde Jonas - Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in B-cell malignancies, but its application in acute myeloid leukemia (AML) and renal cell carcinoma (RCC) remains challenging due to the lack of ideal target antigens. CD70 is highly expressed on AML and RCC tumor cells, while its expression in normal tissues is largely restricted to activated lymphocytes, making it a promising immunotherapeutic target. However, CD70 expression on activated T cells can trigger fratricide in CD70-targeted CAR-T cells, posing a major challenge for their preparation and efficacy. Using an analog of the clinical-stage anti-CD70 antibody ARGX-110 as a reference, we screened a phage display library from immunized mice and identified high-affinity anti-CD70 antibodies, which were then used to construct a panel of second-generation CARs. Functional characterization identified a lead candidate, A174-CAR-T, with high CAR expression, strong in vitro antitumor activity, and low fratricide. We further humanized its single-chain variable fragment to generate A174-hu1-CAR. Compared with the parental construct, A174-hu1-CAR-T cells exhibited enhanced expansion and markedly reduced surface expression of CD70, consistent with improved cis-masking (i.e., surface shielding on the same cell). Molecular docking and surface electrostatic potential analyses suggested that humanization optimized the scFv-CD70 binding interface, which together with increased CAR surface expression contributed to the enhanced masking and reduced fratricide. Functionally, A174-hu1-CAR-T cells maintained potent cytotoxicity and showed enrichment of proliferative and central memory T-cell subsets. In xenograft models, A174-hu1-CAR-T infusion demonstrated potent antitumor efficacy against both AML and RCC, with a favorable safety profile. Overall, we developed a humanized CD70-targeted CAR-T cell therapy, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development. - Source: PubMed
Publication date: 2026/08/27
Zhang MengjiaWang ZhihaoGao ChengWang TingtingZhao JinpingZhu KaixuanWu HuitingLiu ChangWu QiongQiao YanChai YurongJiang YananWang TaoLi GuomingZhao JiminLiu Kangdong